Suppl. figure 1

Oct 24, 2014

10 likes | 130 Views

Suppl. figure 1. A. B. C. pTOPHAbIII. pTOPHAbV. pLPC-EGFP. pTOPHAbI. α-HA. α - β -actin. control. β I. β III. β V. HEK293 T cells.

Share Presentation

Embed Code

Link

iii
plpc egfp
figure 1

marlow

Download Presentation

Suppl. figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Suppl. figure 1 A B C pTOPHAbIII pTOPHAbV pLPC-EGFP pTOPHAbI α-HA α-β-actin control βI βIII βV HEK293 T cells

Suppl Figure 1.

Suppl Figure 1. . Supplementary figure S1: Dose-response curves BL: baseline measurement; H/N: measurement after randomisation to hypoxia or normoxia . Open symbols represent normoxic rats, closed symbols are hypoxic rats.

179 views • 6 slides

Suppl. Figure 1

Suppl. Figure 1. ( ng /ml). IL-6 in cell supernatant. IL-6 in animal serum. *. *. *. *. CV IL6SV CV IL6SV. CV IL6SV CV IL6SV. TRAMP-C1. TRAMP-HR. TRAMP-HR. TRAMP-C1. Suppl. Figure 2. IHC CD31. IHC Ki-67. TRAMP-C1. TRAMP-HR.

161 views • 2 slides

Suppl. Figure 4

A. DMSO. DMH1. 10 4. 14% of CD56 hi. 7% of CD56 hi. 10 3. CD56. 10 2. 7 % of CD56 Int. 3% of CD56 Int. 10 1. 0. 0. 10 1. 10 2. 10 3. 10 4. IFN- . B. IL-2. 20 ng /ml. 5 0 ng /ml. Only. + 20  M DMH1. 0. 10 1. 10 2. 10 3. 10 4. CFSE. C. IL-15.

98 views • 1 slides

Suppl. Figure 3

A. NKG2D. IL-2 + IL-12 +/- Dorsomorphin (  M). 100. 80. 60. % Max. 0. 1. 40. 20. 2. 5. 0. 10 0. 10 1. 10 2. 10 3. 10 4. 100. DMSO C ontrol. 80. 60. % Max. 40. 20. 0. 10 0. 10 1. 10 2. 10 3. 10 4. B. IL-2 + IL-12. + DMSO. (  M). + Dorsomorphin.

149 views • 1 slides

SUPPL FIGURE 1

SUPPL FIGURE 1. SUPPL FIGURE 2. A. B. --. Cal-A. LY294002. SUPPL FIGURE 3. CGP. CGP + ZNT. CGP + ZNT + ROL. A. B. SUPPL FIGURE 4. A. B. EXT. CAVEOLA. CAVEOLA. INT. G α s. G α s. G α i. G α s. . . β 2. β 2. β 2. β 2. P. P. P. P. AC. AC. AC. AC. . P. I-1.

177 views • 4 slides

Suppl. Figure 1

Suppl. Figure 1.

113 views • 1 slides

Suppl . Figure 1

Suppl . Figure 1. A. B.

117 views • 1 slides

Suppl Figure 4

500. 500. 500. 500. 400. 400. 400. 400. 300. 300. 300. 300. 200. 200. 200. 200. 100. 100. 100. 100. 0. 0. 0. 0. 0. 0. 0. 0. 200. 200. 200. 200. 400. 400. 400. 400. 600. 600. 600. 600. 800. 800. 800. 800. 500. 400. 300. 200. 100. 0. a. b. 20.

112 views • 1 slides

Suppl Figure 1

Suppl Figure 1. Growth characteristics of CHO-K1 wt and CKiD cells:

184 views • 3 slides

Suppl Figure 1

250. 200. 150. 100. 50. 0. Th0. Th1. Th2. Liver. Th17-2. Th17-1. Th17-3. Tbet. 400. GATA3. 300. 200. 400. 100. 300. 0. 200. 100. 0. Suppl Figure 1. a. b. c. AhR. FoxP3. AhR. 1000. 15. mRNA level to HPRT (x10 -3 ). mRNA level to HPRT (x10 -3 ).

130 views • 1 slides

Suppl. Figure 1

Suppl. Figure 1. A. B. C. D. PC3. HMEC-1. HUVEC. Suppl. Figure 2. A. B. C. Suppl. Figure 3. A. DKK1-siRNA. nt-siRNA. B. Suppl. Figure 4. A. B. --- ZOL placebo. 12. 6. 0. 12. 6. 0. months. months.

192 views • 4 slides

Suppl Figure 1

Suppl Figure 1. B. A. NSCLC. OvCa. Ep.Ag. CD45. CD3. CD4+/ FoxP3+. CD3-/ CD56+. CD14. CD19. Ep.Ag. CD45. CD3. CD4+/ FoxP3+. CD3-/ CD56+. CD14. CD19.

150 views • 2 slides

Suppl. Figure 1:

Suppl. Figure 1:. A. B. 31.9%.

84 views • 1 slides

Suppl. Figure 4

WT. ap2c1. AP2C1-oe. Suppl. Figure 4: Effect of AP2C1 on disease resistance Representative pictures show necroses on leaves of WT, ap2c1 and AP2C1-oe plants (line #640.2) infected with B. cinerea mycelium applied on agar plugs 4 days post inoculation. Suppl. Figure 4.

94 views • 1 slides

Suppl. Figure 2

Infect TIVE with BCBL-1 virus. TIVE KSHV + day 7 Ad-orf50 day 4. SLK KSHV + Ad-orf50. TIVE KSHV + day 7. TIVE KSHV -. 4 days post Inf. LANA IFA. K8.1. Induce lytic cycle TPA 6 days. Purify virus from TIVE; infect fresh TIVE cells. LANA IFA 4 days post Inf. Repeat 3 times.

122 views • 1 slides

Suppl. Figure 1

Suppl. Figure 1. 1: Hematological system development and Function. 2: Cellular movement. 3: Immune cell trafficking. 4: Cell-to-cell signaling and interaction. 5: Inflammatory response. 6: Small molecular chemistry. 7: Lipid metabolism. 8: Molecular transport. 9: Tissue development.

168 views • 4 slides

Suppl. Figure 1

Suppl. Figure 1. A. C. B. SLD. SPD. RLD. RPD. 5988. 1694. 94. 387. 64. 194.

126 views • 1 slides

Suppl. Figure 4

Suppl. Figure 4. K562. OSPC-2. 37.5 %. a). OSPC-2. K562. 1.45 %. FL4-H: scFvH6-Alexa647. FL4-H: scFvH6-Alexa647. b). A10-CLIP. A10-HALO.

153 views • 1 slides

Suppl. Figure 1

Suppl. Figure 1. VHH-tag fusions Only cytoplasmic? cyto / periplasmic Only periplasmic ?. Toxin. C-tag. SORT. CLIP. SNAP. POX. GFP. Fc. CYS. BS. AP. HALO.

137 views • 1 slides

Suppl. Figure 2

Suppl. Figure 2.

90 views • 1 slides

Suppl. Figure 1

A. B. Suppl. Figure 1.

71 views • 1 slides

Suppl Figure 5

Suppl Figure 5. MB947. MB1337. MB1547. Immunoblot of Effector Proteins in Tumors from PDTX Mice Treated with TAK-733. TAK-733. vehicle. S6. vehicle. vehicle. TAK-733. TAK-733. pS6. AKT. pAKT. ERK. pERK 1/2. α-tubulin. S. TGI Response. R. S. WT. BRAF Status. V600E. V600E.

117 views • 1 slides

More Related